-
公开(公告)号：US20150044246A1
公开(公告)日：2015-02-12
申请号：US14503690
申请日：2014-10-01
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Hans Georg RAMMENSEE
CPC classification number: C12Q1/6876 , A61K38/04 , A61K39/00 , A61K2039/55 , A61K2039/572 , C07K7/00 , C07K14/4748 , C12Q1/6837 , C12Q2600/136 , C12Q2600/158 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/57484 , G01N33/68
Abstract: The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample of tumorous and corresponding healthy tissue is first provided, the tumor-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analyzed. The respective data that has been obtained is then matched and peptides are identified on the basis of said data.
Abstract translation: 本发明涉及鉴定免疫反应肽的方法。 根据所述方法，首先提供肿瘤和相应的健康组织的样品，随后确定肿瘤特异性表达谱，并从肿瘤组织中分离抗原肽。 然后将所获得的相应数据进行匹配，并且基于所述数据识别肽。
-
492.发明申请公开(公告)号：US20250074961A1
公开(公告)日：2025-03-06
申请号：US18947499
申请日：2024-11-14
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Valentina GOLDFINGER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61K39/00 , C07K7/06 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115 , C12N15/62 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20240425558A1
公开(公告)日：2024-12-26
申请号：US18760718
申请日：2024-07-01
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
494.发明公开公开(公告)号：US20240350602A1
公开(公告)日：2024-10-24
申请号：US18759376
申请日：2024-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , A61K35/17 , A61K38/08 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/115
CPC classification number: A61K39/0011 , A61K35/17 , A61K38/08 , C07K7/06 , C07K7/08 , C07K14/001 , C07K14/70539 , C07K16/2833 , C12N5/0638 , C12N15/115 , A61K2039/5158 , C07K2319/00 , C12N2310/16 , C12N2501/2302 , C12N2501/2307 , C12N2501/51 , C12N2501/515
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
495.发明公开公开(公告)号：US20240285738A1
公开(公告)日：2024-08-29
申请号：US18647775
申请日：2024-04-26
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , A61K35/17 , A61K38/00 , A61K39/39 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115
CPC classification number: A61K39/0011 , A61K39/39 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N15/115 , A61K35/17 , A61K38/00 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/572 , C07K2317/34 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
496.发明公开公开(公告)号：US20240280583A1
公开(公告)日：2024-08-22
申请号：US18638970
申请日：2024-04-18
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Julia LEIBOLD
IPC: G01N33/68 , G01N33/569
CPC classification number: G01N33/6848 , G01N33/56977 , G01N33/6842 , G01N33/6878 , G01N2333/70539 , G01N2458/15 , G01N2496/00 , G01N2560/00 , G01N2570/00
Abstract: The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.
-
497.发明公开公开(公告)号：US20240016908A1
公开(公告)日：2024-01-18
申请号：US18451216
申请日：2023-08-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Phillip MUELLER , Julia LEIBOLD , Valentina GOLDFINGER
IPC: A61K39/00 , C12N5/0783 , C07K14/725
CPC classification number: A61K39/4632 , C12N5/0636 , C07K14/7051 , A61K2039/55533 , A61K2039/55538 , A61K2039/55527
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
498.发明公开公开(公告)号：US20230382964A1
公开(公告)日：2023-11-30
申请号：US18448614
申请日：2023-08-11
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K16/28 , C07K7/06 , A61P35/00 , C07K14/725 , C07K14/54 , C07K14/74 , A61K39/00 , C12N15/115 , C12N15/10 , A61K35/17 , C12N5/0783 , G01N33/574 , C07K16/30
CPC classification number: C07K14/4748 , C07K16/2818 , C07K7/06 , A61P35/00 , C07K14/7051 , C07K14/5434 , C07K14/70539 , A61K39/0011 , C12N15/115 , C12N15/1062 , A61K35/17 , A61K39/001102 , C12N5/0638 , G01N33/57492 , C07K16/30 , A61K2039/5158 , A61K2039/572 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
499.发明公开公开(公告)号：US20230331807A1
公开(公告)日：2023-10-19
申请号：US18314727
申请日：2023-05-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH , Gisela SCHIMMACK , Michael ROEMER
IPC: G01N33/574 , C07K16/28 , A61K9/19 , A61K39/00 , G16B25/10 , C07K14/725 , C12N15/115 , C12N5/0783 , A61P35/00 , C07K14/74 , A61K35/17
CPC classification number: C07K14/7051 , A61K9/19 , A61K35/17 , A61K39/001111 , A61P35/00 , C07K14/70539 , C07K16/2809 , C07K16/2833 , C12N5/0638 , C12N15/115 , G01N33/57492 , G16B25/10 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
500.发明公开公开(公告)号：US20230265140A1
公开(公告)日：2023-08-24
申请号：US18189448
申请日：2023-03-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12Q1/6886 , G16B25/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
623
records
(took 0.026 seconds)
